Efficacy, Safety, and Pharmacokinetics (PK) of Azacitidine (AZA) in Children and Young Adults with Acute Myeloid Leukemia (AML) in the Phase 2 AZA-AML-004 Trial

Dirk Reinhardt,Henrik Hasle,Karsten Nysom,André Baruchel,Franco Locatelli,Bouchra Benettaib,Noha Biserna,Meera Patturajan,Mathew Simcock,Allison Gaudy,C Michel Zwaan

doi:10.1182/blood-2020-137043

Efficacy, Safety, and Pharmacokinetics (PK) of Azacitidine (AZA) in Children and Young Adults with Acute Myeloid Leukemia (AML) in the Phase 2 AZA-AML-004 Trial

Dirk Reinhardt, Henrik Hasle + Show 9 more

Open Access

https://doi.org/10.1182/blood-2020-137043

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2020
Citations: 2

Affiliation: Essen University Hospital, Aarhus University Hospital, Rigshospitalet, Hôpital Robert-Debré, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Bambino Gesù Children's Hospital, Istituti di Ricovero e Cura a Carattere Scientifico, Sapienza University of Rome, Bristol-Myers Squibb (United States), Bristol-Myers Squibb (United Kingdom), Princess Máxima Center, Erasmus MC - Sophia Children’s Hospital

#Equity Holder In Publicly-traded Company #Efficacy Of Azacitidine + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Efficacy, Safety, and Pharmacokinetics (PK) of Azacitidine (AZA) in Children and Young Adults with Acute Myeloid Leukemia (AML) in the Phase 2 AZA-AML-004 Trial

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.